Problem and user
Describe the operational problem, affected users or organizations, present alternatives, and why the issue matters without revealing the enabling solution.
Enough to qualify • Not enough to enable
Non-Confidential Technical Brief
A strong first brief lets a serious counterparty evaluate relevance, maturity, fit, and the proposed next step while preserving unfiled invention detail, trade secrets, controlled data, and private business records.
Public scopeNon-confidential structure, readiness, and inquiry routing.
Evidence languageConcept, analysis, simulation, prototype, and test remain
distinct.
No implied statusNo patent, funding, clearance, partnership, or job claim without
verification.
Controlled detailEnabling, restricted, personal, and privileged records remain
offline.
Structure
Operating framework
The public page explains the decision structure while detailed records remain controlled offline.
Proposed capability
State the intended function, system boundary, interfaces, and potential application in careful language that distinguishes concept from tested performance.
Evidence and maturity
Identify what exists—research, requirements, calculations, simulations, CAD/renderings, benchtop work, prototype, test, or independent evidence—and what does not.
Rights and disclosure
State that non-confidential materials are supplied for discussion, identify known public records, and avoid patent-status claims not supported by counsel-approved facts.
Development need
Define the next technical milestone, resources, facilities, expertise, regulation, safety work, and estimated decision—not a sweeping funding request.
Requested relationship
Specify whether Aurora seeks expert review, research collaboration, manufacturing input, evaluation, licensing, sponsored development, or another bounded next step.
Sequence
Decision sequence
Each stage produces a reviewable record before the next commitment is made.
01 — DraftUse approved public facts and evidence labels.
02 — Technical reviewCheck accuracy, assumptions, maturity, and prohibited
claims.
03 — Rights reviewCheck patent, copyright/license, trademark, secrecy, and
disclosure history.
04 — Compliance reviewCheck export, FDA/device, safety, privacy, securities, and
sponsor rules.
05 — ReleaseIssue a dated revision, recipient purpose, and next-step
route.
Important limit: Do not use “patented,” “patent
pending,” “validated,” “certified,” “FDA approved,” “investment
opportunity,” or similar language unless the underlying fact and
permitted wording have been verified.
Primary references
Official starting points
Requirements change. Confirm the current rule, program, or filing path with the responsible agency and qualified professional.
USPTO — Provisional patent applications ↗U.S. Copyright Office — Works not protected by copyright ↗FDA — Device Advice ↗SEC — Resources for small businesses raising capital ↗
Official links and public guidance reviewed August 2, 2026.
Continue